Advertisement
Advertisement
NMRA
Neumora Therapeutics, Inc. Common Stock
1.85
USDSponsored
0.00
0.00%
May 22, 16:00 UTC -4
Closed
After-Market
1.91
+0.05
+2.97%
NMRA Earnings Reports
Positive Surprise Ratio
NMRA beat 6 of 11 last estimates.
55%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
--
/-16.67%
Implied change from Q2 25 (Revenue/ EPS)
--
/-24.24%
Neumora Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, NMRA reported earnings of -0.30 USD per share (EPS) for Q1 26, beating the estimate of -0.31 USD, resulting in a 5.12% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -16.74% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an decrease of -16.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immuneering Corporation Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.29%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Rein Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.19
Surprise
+61.98%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
FAQ
What were Neumora Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 5.12%, and revenue of $0.00, 0% as expectations.
How did the market react to Neumora Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -16.74%, changed from $2.33 before the earnings release to $1.94 the day after.
When is Neumora Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Neumora Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement